Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?

por Ferrannini, Ele, Rosenstock, Julio
Publicado 2021

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646

por Ferrannini, Ele, Rosenstock, Julio
Publicado 2021

What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?

por Bonde, Lawrence, Rosenstock, Julio, Triplitt, Curtis
Publicado 2006

SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients : Effects of monotherapy with rimonabant, the first selective CB(1) receptor antagonist, on glyce...

por Rosenstock, Julio, Hollander, Priscilla, Chevalier, Soazig, Iranmanesh, Ali
Publicado 2008

Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance

por Cefalu, William T., Rosenstock, Julio, Henry, Robert R., Riddle, Matthew
Publicado 2013

Glycated Albumin Correlates With Time-in-Range Better Than HbA(1c) or Fructosamine

por Desouza, Cyrus V, Rosenstock, Julio, Kohzuma, Takuji, Fonseca, Vivian A
Publicado 2023

Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: A double-blind placebo-controlled trial

por Arezzo, Joseph C, Rosenstock, Julio, LaMoreaux, Linda, Pauer, Lynne
Publicado 2008

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing

por Rosenstock, Julio, Reusch, Jane, Bush, Mark, Yang, Fred, Stewart, Murray
Publicado 2009

Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study

por Skyler, Jay S., Fonseca, Vivian A., Segal, Karen R., Rosenstock, Julio
Publicado 2015

Insulin’s Role in Diabetes Management: After 90 Years, Still Considered the Essential “Black Dress”

por Cefalu, William T., Rosenstock, Julio, LeRoith, Derek, Riddle, Matthew C.
Publicado 2015

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

por Riddle, Matthew, Umpierrez, Guillermo, DiGenio, Andres, Zhou, Rong, Rosenstock, Julio
Publicado 2011

Response to Comment on: Riddle et al. Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Dia...

por Riddle, Matthew, Umpierrez, Guillermo, DiGenio, Andres, Zhou, Rong, Rosenstock, Julio
Publicado 2012

Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy

por Rosenstock, Julio, Vico, Marisa, Wei, Li, Salsali, Afshin, List, James F.
Publicado 2012

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes

por Rosenstock, Julio, Perl, Shira, Johnsson, Eva, García‐Sánchez, Ricardo, Jacob, Stephan
Publicado 2019

Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes

por Skolnik, Neil, Del Prato, Stefano, Blonde, Lawrence, Galstyan, Gagik, Rosenstock, Julio
Publicado 2021

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

por Rosenstock, Julio, Mathieu, Chantal, Chen, Hungta, Garcia-Sanchez, Ricardo, Saraiva, Gabriela Luporini
Publicado 2018

Getting to the “Heart” of the Matter on Diabetic Cardiovascular Disease: “Thanks for the Memory”

por Cefalu, William T., Rosenstock, Julio, LeRoith, Derek, Blonde, Lawrence, Riddle, Matthew C.
Publicado 2016

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type...

por Rosenstock, Julio, Fonseca, Vivian, Schinzel, Stefan, Dain, Marie-Paule, Mullins, Peter, Riddle, Matthew
Publicado 2014

Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

por Gomez‐Peralta, Fernando, Al‐Ozairi, Ebaa, Jude, Edward B., Li, Xiaoying, Rosenstock, Julio
Publicado 2021

Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials

por Mosenzon, Ofri, Capehorn, Matthew S., De Remigis, Alessandra, Rasmussen, Søren, Weimers, Petra, Rosenstock, Julio
Publicado 2022